Two more patients bolster Sangamo’s haemophilia A gene therapy
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
As Genfit deals and Conatus folds, Nash plays on
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
Krystal plays down dropout to claim a mid-stage win
Despite concerns about a missing patient, results from a tiny trial in epidermolysis bullosa boosted Krystal Biotech’s stock by 41%.
German Merck watches evobrutinib’s benefit melt away
Merck KGaA’s BTK inhibitor had been hailed as the first to show activity in multiple sclerosis, but full clinical results cast doubt on this claim.
G1 makes the most of trilaciclib's unclear survival benefit
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.
Questions surround Bone Therapeutics’ spine data
The company needed a hit in its spine trial, and it claims to have got one.
Why investors should question Savara's excuse
With the company’s Molgradex failing to beat standard of care in a rare lung disorder, the premise behind this project looks questionable.
Achieve goes up in smoke
Achieve Life Sciences gets a reality check despite largely positive smoking cessation data.
Cymabay can’t buck the Nash disappointment trend
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.